Gemcitabine-containing chemotherapy in the treatment of patients with advanced soft tissue sarcoma;Gemcitabinhaltige chemotherapie in der behandlung von patienten mit fortgeschrittenen weichteilsarkomen

Tumor Diagnostik und Therapie

Volumn 23, Issue 6, 2002, Pages 219-224

  Bauer, Sebastian ^a   Hartung, J ^a   Gauler, T ^a   Gocke, P ^a   Trarbach, T ^a   Flasshove, M ^a   Nowrousian, M R ^a   Bojko, P ^a   Hense, J ^a   Seeber, S ^a   Schutte J ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Gemcitabine; Second line therapy; Soft tissue sarcomas; Third line therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANEMIA; ANGIOSARCOMA; ARTICLE; BONE MARROW TOXICITY; BONE PAIN; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; FEMALE; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HUMAN; INFECTION; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; MALE; REMISSION; SOFT TISSUE CANCER; SOFT TISSUE SARCOMA; STOMATITIS; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036967356     PISSN: 0722219X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36487     Document Type: Article

References (18)

1. Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 1998; 78: 1634-1639
2. Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissuesarcomas. J Clin Oncol 1995; 13: 1600-1608
3. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000; 36: 61-67
4. Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991; 2: 307-309
5. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5: 840-850
6. Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 2001; 19: 1248-1255
7. Le Cesne A, Blay JY, Judson I, et al. ET-743 is an Active Drug in Adult Soft-Tissue Sarcoma (STS): a STBSG-EORTC Phase II Trial. Proc Am Soc Clin Oncol 2001; 20: 353a (abstr)
8. Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000; 45: 177-181
9. Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000; 11: 325-329
10. Okuno SH, Edmonson JH, Mahoney MR, Buckner JC, Frytak S, Galanis E. Limited activity and acceptable toxicity of gemcitabine in a phase II study of patients with advanced sarcomas: a Mayo Cancer Center study. Proc Am Soc Clin Oncol 2000; 19: 555a(abstr)
11. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20: 2824-2831
12. Svancarova L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase 11 study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38: 556-559
13. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001; 19: 3483-3489
14. van Glabbeke M, Hogendoorn PCW, Mouridsen H, et al. Progression free rate as the principal end-point for phase II trial on soft tissue sarcoma: what should be the target? A retrospective study of the EORTC Soft Tissue and Bone Sarcoma (STBSG) database. Proc Am Soc Clin Oncol 2001; 20: 354a(abstr)
15. van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-549
16. Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18: 2081-2086
17. Blackledge G, van Oosterom A, Mouridsen H, et al. Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer 1990; 26: 139-141
18. Keohan ML, Grever MR, Balcerzak SP, Antman K. A phase II Southwest Oncology Group study of cisplatin and continuous infusion vinblastine in the treatment of advanced soft tissue sarcoma. Invest New Drugs 1997; 15: 255-256